This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Spectrum Pharmaceuticals, Inc.
Drug Names(s): SPI-1620
Description: SPI-1620 is a highly selective peptide endothelin-B agonist that causes a selective and transient increase in blood flow to tumors, thereby increasing the delivery of anticancer agents to the tumor, and as a result increasing the efficacy of these drugs.
In pre-clinical studies, when anti-cancer drugs, such as paclitaxel, doxorubicin, cisplatin, 5-FU, cyclophoshamide and others, are administered shortly after SPI-1620, the anti-cancer drug concentration in the tumor is increased several fold. This results in increased anti-tumor efficacy at a given dose of a cytotoxic agent, and might allow physicians to maximize efficacy with reduced cytotoxic agent doses with resultant decreased toxicity to the normal organs.
Deal Structure: In February 2005, Spectrum acquired an exclusive worldwide license to develop and commercialize SPI-1620 for the prevention and treatment of cancer from Chicago Labs. Spectrum paid Chicago Labs a small up-front fee and is obligated to make future payments contingent upon the successful achievement of certain development and regulatory milestones. In addition, Spectrum will pay royalties and sales milestones on net sales, after marketing approval is obtained.
Additional information available to subscribers only: